Skip to main content

Year: 2021

AEP Ticketing Solutions Joins Modaxo

TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) — Modaxo Inc. (“Modaxo”), a global technology organization focused on moving the world’s people, today announced the acquisition of AEP Ticketing solutions s.r.l. (“AEP”), a leading provider of eTicketing solutions to the public transport industry. AEP brings to Modaxo a rich history in providing innovative software and hardware solutions that covers all aspects of ticketing — from the most traditional to the most advanced such as eCommerce, Account-based Ticketing, and EMV bank cards. Based in Italy, the company has amassed 500+ customers over its 20+ year history. “eTicketing in the public transport space has evolved considerably and rapidly over the past decade and AEP has played a key role in driving innovation in this space,” said Bill Delaney, CEO, Modaxo. “It’s a great pleasure...

Continue reading

Methode Electronics, Inc. Reports Fiscal Second Quarter 2022 Financial Results

Record Electric and Hybrid Vehicle Application Sales Strong Industrial Segment Sales $34.8 Million in Share BuybacksCHICAGO, Dec. 02, 2021 (GLOBE NEWSWIRE) — Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interface, LED lighting and power distribution applications, today announced financial results for the second quarter of fiscal 2022 ended October 30, 2021. Fiscal Second Quarter 2022 HighlightsNet sales were $295.5 million Electric and hybrid vehicle applications were 16 percent of net sales, a record in dollars Net income was $27.5 million, or $0.72 per diluted share Company purchased 807,516 shares of its common stock for $34.8 millionConsolidated Fiscal Second Quarter 2022 Financial ResultsMethode’s net sales were $295.5 million, which included a favorable...

Continue reading

Titan Declares 2nd Cash Dividend of Approximately C$1.4 million; Fixes US$1.50/lb Zinc Price for 60% of Q1 2022 Budgeted Production

VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) — Titan Mining Corporation (TSX: TI) (“Titan” or the “Company”) announces that its Board of Directors has declared a special cash dividend of C$0.01 per common share (the “Dividend”) for an aggregate distribution of approximately C$1.4 million based on the current number of shares outstanding. Titan also announces that it has entered into a fixed zinc pricing arrangement pursuant to its existing offtake agreement with an affiliate of Glencore plc for 60% of the Company’s budgeted zinc production for the first quarter of 2022 at a price of US$1.4954 per pound of zinc. Don Taylor, President and CEO, commented, “This second consecutive special dividend meets the Company’s intention to pay regular quarterly dividends with the gradual increase in production at its Empire State...

Continue reading

WESTPAY AND EASYCASHIER COMPLETE SUCCESSFUL LAUNCH OF MULTI-USER PAYMENT SOLUTION

Westpay AB, a leading fintech company, has enabled multi-user functionality (MultiTID) in their payment application. This solution makes it possible for several users to share a physical payment solution. This is in demand in several verticals, such as hairdressers, who share premises but run their business individually. EasyCashier, a leading POS provider and a close partner to Westpay will be the first partner that offer this solution for their customers. – Again, I am proud that Westpay continues to push the limits to what you can expect from a payment solution. We have seen this functionality before, but the way we manage to simplify the use of sharing payment solutions. It is also happy that EasyCashier embraces this solution and enables it for their customers. They are a solid, reliable partner with great expertise and experience,...

Continue reading

Duluth Holdings Inc. Announces Third Quarter 2021 Financial Results

Net Sales of $145 million increase 7.2% compared to Q3 2020 and 21.3% compared to Q3 2019 Gross Margin reaches record third quarter rate of 57.6% Raises Full Year 2021 EPS outlook to $0.81 to $0.86 MOUNT HOREB, Wis., Dec. 02, 2021 (GLOBE NEWSWIRE) — Duluth Holdings Inc. (dba, Duluth Trading Company) (“Duluth Trading” or the “Company”) (NASDAQ: DLTH), a growing lifestyle brand of men’s and women’s workwear, casual wear, outdoor apparel and accessories, today announced its financial results for the fiscal third quarter ended October 31, 2021. Highlights for the Third Quarter Ended October 31, 2021Net sales increased 7.2% to $145.3 million compared to $135.5 million in the third quarter of 2020 and increased 21.3% when compared to the same period in 2019 Gross margin improved 520 basis points to 57.6% compared to 52.4% in the prior...

Continue reading

Lands’ End Announces Third Quarter Fiscal 2021 Results

Net Revenue grew 4.4% compared to the same period last yearNet Income of $7.4 million, compared to a Net Income of $7.2 million in the same period last yearAdjusted EBITDA of $29.8 million at the high-end of outlookCyber Week Sales Increased High Single Digits over 2020 DODGEVILLE, Wis., Dec. 02, 2021 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) today announced financial results for the third quarter ended October 29, 2021 and sales results for Cyber Week, and provided fourth quarter and an updated full year outlook. Jerome Griffith, Chief Executive Officer, stated, “Our third quarter performance reflects the long-term strength and resiliency of our digitally led business model, as we navigated the dynamic global supply chain challenges while still delivering on our Adjusted EBITDA expectations. We achieved 4% topline growth...

Continue reading

Harboes Bryggeri A/S – Interim report for H1 2021/22

Today, the Board of Directors of Harboes Bryggeri A/S has discussed and approved the following interim report for the first half of 2021/22. Skælskør, 2 December 2021Bernhard Griese, Chairman & Claus Christian Bayer, Deputy chairman In this connection, CEO Søren Malling states: “We are pleased that our sales continue to develop positively driven in particular by export markets, where targeted sales eff orts ensure progress with both existing and new customers in all regions. But we also note that the current challenges of raw  material shortages, rising commodity prices and freight capacity constraints are affecting both sales and earnings in Q2. We are fully focused on operating as efficiently as possible under the given market conditions, and implemented optimisations of both fixed and unit costs in our product range in Q2...

Continue reading

Progenity Announces New Patent for Single-Molecule Detection Technology

SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, today announced a new patent related to its single-molecule detection platform under development. The USPTO has issued U.S. Patent No. 11,186,863 entitled, “Methods, Systems, and Compositions for Counting Nucleic Acid Molecules.” The issued claims cover methods for capturing, amplifying, and imaging single copies of target nucleic acid molecules. “This patent covers critical methods for counting target molecules, obviating the need for sequencing,” said Matthew Cooper, General Manager, Diagnostics. “Our Single-Molecule Detection Platform is designed to enable tests such as noninvasive prenatal testing (NIPT) or liquid biopsy for cancer to be performed without...

Continue reading

Veru Reports Record Fiscal 2021 Full-Year Financial Results

–FY21 Net Revenues Increase 44% to $61 Million and Gross Profit Increases 56% to $48 Million, Achieving New Historical Highs– –Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of Hospitalized Moderate to Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome Being Conducted in US, Mexico, South America, and Europe; Clinical Results Expected 1H 2022– –Expansive Breast Cancer Program Continues Its Rapid Advance; Four Late-Stage Clinical Studies Enrolling or Planned in Metastatic Breast Cancer– –Phase 3 VERACITY Clinical Study of Oral, Targeted, Cytoskeleton Disruptor Sabizabulin for Metastatic Castration Resistant Prostate Cancer Enrolling– –Phase 2 Dose Finding Clinical Study of VERU-100 Long-Acting GnRH Antagonist Peptide, SubQ, 3-Month, Depot Injection...

Continue reading

X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor

Company to present new clinical data supporting the expanded potential use of mavorixafor to treat a broad array of immunodeficiencies as well as new insights into WHIM syndrome Guest speakers include thought leaders with expertise in the research and treatment of rare immunodeficiencies Webcast to take place following ASH Annual Meeting on December 16, 2021 at 8:30 a.m. EST BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with immune system dysfunction, today announced that it will host a virtual seminar “Understanding Primary Immunodeficiencies” on Thursday, December 16, 2021 at 8:30 a.m. EST to discuss new clinical data on mavorixafor, X4’s late-stage clinical candidate, and new research...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.